Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.

Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.

Abstract: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to extract the polymerized medical devices with water. This avoids the use of organic solvents as is typical in the art. The polymeric compositions comprise polymerized cationic hydrophilic siloxanyl monomers prepared by the process disclosed herein.

Abstract: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Abstract: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Abstract: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Abstract: Matrix controlled diffusion drug delivery systems are described herein which are based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to extract the polymerized medical devices with water. This avoids the use of organic solvents as is typical in the art. The polymeric compositions comprise polymerized cationic hydrophilic siloxanyl monomers prepared by the process disclosed herein.

Abstract: Biomedical devices such as contact lenses formed from a polymerization product of a mixture comprising (a) a hydrophilic polymer comprising one or more hydrophilic units and one or more thio carbonyl thio fragments of a reversible addition fragmentation chain transfer (“RAFT”) agent; and (b) one or more biomedical device-forming monomers are disclosed.

Abstract: A contact lens is coated with a first polymer, such as a boronic acid-containing copolymer, having affinity to mucin, and a second polymer. The second polymer improves initial comfort of the contact lens. During wear of the contact lens, the second polymer is removed from the contact lens, by blinking and/or tear fluids, and mucin complexes with the first polymer on the contact lens surface.

Abstract: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain cationic monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. Such properties include the ability to extract the polymerized medical devices with water. This avoids the use of organic solvents as is typical in the art. The polymeric compositions comprise polymerized cationic hydrophilic siloxanyl monomers prepared by the process disclosed herein.

Abstract: Disclosed are silicone-containing contact lenses having an overall additive thickness less than or equal to about 310 ?m.

Abstract: At least one of the surfaces of a silicone contact lens is a wrinkled surface, providing the contact lens surface with a desired topography. The wrinkled surface may include random ridges, either over the entire surface of the lens, or in a desired pattern on the surface of the lens.

Abstract: The use of compositions containing one or more antimicrobial agents with one or more trialkanolamine alkoxylate buffers to disinfect and/or preserve medical devices is described. Solutions containing one or more antimicrobial agents with one or more trialkanolamine alkoxylate buffers and methods of making and using the same are also described.

Abstract: At least one of the surfaces of a silicone contact lens is a wrinkled surface, providing the contact lens surface with a desired topography. The wrinkled surface may include random ridges, either over the entire surface of the lens, or in a desired pattern on the surface of the lens.

Abstract: Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: Matrix controlled diffusion drug delivery systems are described herein which are based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.

Abstract: A process for treating a silicone hydrogel biomedical device, especially an ophthalmic lens such as a contact lens, involves: immersing the silicone hydrogel biomedical device with a mixture of an organic solvent and a hydrophilic, polymeric material, for a sufficient time that the device is swollen in volume by at least 30%; and removing the organic solvent from the device while retaining at least a portion of the hydrophilic polymeric material therein.